Fei Cao

Fei Cao

Auto-generated profile, based on publicly available information

Fei Cao

Department of Minimally Invasive Therapy, Sun Yat-sen University Cancer Center

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DWDi Wu
Di Wu
YLYong Li
Yong Li
PXPengfei Xu
Pengfei Xu
QFQi Fang
Qi Fang
FCFei Cao
Fei Cao
XLXuekui Liu
Xuekui Liu
Neoadjuvant chemoimmunotherapy has emerged as a potential treatment option for resectable head and neck squamous cell carcinoma (HNSCC). In this single-arm phase II trial (NCT04826679), patients with resectable locally advanced HNSCC (T2‒T4, N0‒N3b, M0) received neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2), and cisplatin (60 mg/m2) intravenously on day one of each three-week cycle for three cycles. The primary endpoint was the objective response rate (ORR). Secondary endpoints included pathologic complete response (pCR), major pathologic response (MPR), two-year progression-free survival rate, two-year overall survival rate, and toxicities. Here, we report the perioperative outcomes; survival outcomes were not mature at the time of data analysis. Between April 19, 2021 and March 17, 2022, 48 patients were enrolled and received neoadjuvant therapy, 27 of whom proceeded to surgical resection and remaining 21 received non-surgical therapy. The ORR was 89.6% (95% CI: 80.9, 98.2) among 48 patients who completed neoadjuvant therapy. Of the 27 patients who underwent surgery, 17 (63.0%, 95% CI: 44.7, 81.2) achieved a MPR or pCR, with a pCR rate of 55.6% (95% CI: 36.8, 74.3). Treatment-related adverse events of grade 3 or 4 occurred in two patients. This study meets the primary endpoint showing potential efficacy of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin, with an acceptable safety profile, in patients with resectable locally advanced HNSCC.



25 April 2019 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
FCFei Cao
Fei Cao
LXLin Xie
Lin Xie
HQHan Qi
Han Qi
SCShuanggang Chen
Shuanggang Chen
LSLujun Shen
Lujun Shen
WFWeijun Fan
Weijun Fan
Background: The study was conducted to assess the safety and efficacy of thermal ablation for the treatment of subpleural lung cancer.Methods: Eighty‐nine patients with 101 subpleural lung cancers were identified between January 2012 and July 2018 in our database and included in this study. Tumors were classified as adhering to cervical, costal, diaphragmatic, and mediastinal pleurae. Lesions were categorized based on their relationship to the pleura: close to the pleura, causing pleural indentation, and involving the pleura. The complete ablation rate, local progression‐free survival, complications, and associated factors were analyzed.Results: Subpleural lung cancers included lesions located under costal (n = 69), mediastinal (n = 17), cervical (n = 8), and diaphragmatic (n = 7) pleurae. The rate of complete ablation was 87.1% and the local progression‐free survival rates at 3, 6, 12, and 24 months were 86%, 77%, 75%, and 64%, respectively. Tumor size was the most important factor influencing technique efficacy (P < 0.05), with a complete ablation rate of only 55.6% in lung cancers measuring > 30 mm. There were nine (10.11%) major complications, including one chest abscess, five cases of pneumothorax, and three cases of hemothorax. The occurrence of major complications was associated with increased levels of pain within 48 hours post‐procedure (P < 0.05).Conclusion: Local thermal ablation is a safe and effective treatment for subpleural lung cancers. Tumor size was the most significant factor affecting technique efficacy. Post‐procedure pain indicated the possibility of major complications.

12 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
FCFei Cao
Fei Cao
CWChunyong Wen
Chunyong Wen
YWYujia Wang
Yujia Wang
HTHongtong Tan
Hongtong Tan
SHShaohuan Hao
Shaohuan Hao
ZHZi-Lin Huang
Zi-Lin Huang
Background: PD-1/PD-L1 inhibitors have shown efficacy in improving the prognosis of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombosis (PVTT) in pivotal clinical trials including the landmark IMbrave150 study. However, not all the patients benefit from the PD-1/PD-L1 blockade immunotherapy. This study aimed to improve the identification of PVTT-associated HCC patients who may benefit from the combination of PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) and tyrosine kinase inhibitor (TKI) treatment under real-world conditions.Methods: From 377 HCC-PVTT patients receiving HAIC-TKI ± PD-1 inhibitors (2016-2023), we compared 76 dual-therapy (HT) and 175 triple-therapy (HTP) cases. Median follow-up period was 34.8 months in the HT group and 33.4 months in the HTP group (P=0.175). Propensity score matching (1:1 caliper=0.2) was used to balance baseline characteristics. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were evaluated in both groups. Specific subgroups including Vp4 type PVTT, extrahepatic metastases, and patients over 60 years old, were analyzed.Results: Triple therapy significantly improved median OS (24.6 vs. 13.5 months; HR=0.58, 95%CI:0.42–0.80; P=0.001) and PFS (11.1 vs. 6.4 months; HR=0.56, P60 or with extrahepatic metastases.

15 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FCFei Cao
Fei Cao
YLYan Li
Yan Li
QFQi Fang
Qi Fang
RLRuobin Lin
Ruobin Lin
ZZZheng Zhao
Zheng Zhao
XLXuekui Liu
Xuekui Liu
Purpose: Preclinical and clinical findings suggest that PD-1/cytotoxic T lymphocyte–associated protein 4 bispecific antibodies may offer synergistic antitumor activity. This study aimed to explore the efficacy and safety of cadonilimab combined with neoadjuvant chemotherapy in locally advanced, resectable head and neck squamous cell carcinoma. Patients and Methods: Eligible patients were consecutively enrolled and received cadonilimab (10 mg/kg) and chemotherapy (docetaxel, 75 mg/m2 plus cisplatin, 60 mg/m2) every 3 weeks for three cycles. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate, pathologic complete response, major pathologic response (MPR), safety, progression-free survival, and overall survival. Analyses of biomarkers and tumor-infiltrating immune cell subsets were conducted. This study is registered with ClinicalTrials.gov (NCT06023875). Results: Thirty patients were included from July 2023 to December 2023. The median age was 55 years (range: 26–69), and 27 (90.0%) patients were male. The ORR was 83.3%, disease control rate was 100.0%, MPR rate was 76.7%, and pathologic complete response rate was 50.0%. All patients experienced treatment-related adverse events. Grade 3 treatment-related adverse events were reported in 7 (23.3%) patients. Progression-free survival and overall survival data were not yet mature as of the cutoff date (February 1, 2025). Subgroup analysis revealed no significant differences in biomarker expression. A higher baseline infiltration of M1-like macrophages in the tumor stroma was associated with better treatment efficacy. Conclusions: Cadonilimab plus neoadjuvant chemotherapy demonstrated favorable ORR and MPR with manageable toxicities in patients with head and neck squamous cell carcinoma.